We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
Read MoreHide Full Article
Key Takeaways
AbbVie's atogepant cut perimenstrual migraine days by 0.80 versus placebo in the phase III LUNA study.
Atogepant improved headache days, migraine severity, acute medicine use and responder rates.
AbbVie plans to submit LUNA data globally, potentially expanding atogepant's commercial migraine opportunity.
AbbVie (ABBV - Free Report) announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin gene-related peptide receptor antagonist, for preventive treatment of menstrual migraine in adult women. Menstrual migraine is a recurrent and debilitating form of migraine associated with attacks occurring around or during menstruation.
Atogepant is already approved in the United States as Qulipta for the preventive treatment of migraine in adults, while the drug is marketed as Aquipta in the European Union for acutetreatment and migraine prophylaxis in adults.
Year to date, ABBV shares have risen 11.6% compared with the industry’s 10.4% growth.
Image Source: Zacks Investment Research
ABBV’s Atogepant Reports Positive Data Across LUNA Endpoints
The phase III LUNA study evaluated atogepant for the prevention of menstrual migraine in adult women with either pure menstrual migraine or menstrually related migraine. Participants were given atogepant for seven days around the start of their menstrual period for three consecutive cycles.
Atogepant met the study’s primary endpoint, reducing migraine days during the perimenstrual period by an average of 1.20 days compared with 0.40 days with placebo. This resulted in 0.80 fewer migraine days versus placebo.
The drug demonstrated statistically significant and clinically meaningful improvements across the study’s secondary endpoints, including reductions in headache days, moderate-to-severe headache and migraine severity, as well as decreased use of acute migraine medications. Improvements were also observed in functional disability, cognitive function and responder rates. The safety profile remained consistent with the established profile of atogepant, with no new safety signals reported.
AbbVie plans to submit the study data to regulatory authorities worldwide and present the detailed results at future medical meetings.
With no treatment specifically approved for menstrual migraine, the LUNA findings could help address an important unmet need while potentially expanding the commercial opportunity for AbbVie’s established migraine franchise.
LUNA Data Could Expand Atogepant’s Commercial Opportunity
The LUNA study data are particularly important from a commercial perspective because they could broaden the addressable market for Qulipta/Aquipta. Qulipta/Aquipta is already an important growth product within AbbVie’s neuroscience portfolio. It is approved across 60 countries.
In the second quarter of 2026, global Qulipta/Aquipta net revenues reached $350 million, up 30.9% year over yearon a reported basis, while first-half 2026 revenues reached $646 million, representing 40.5% reported growth year over year.
AbbVie markets Ubrelvy (ubrogepant) for acute migraine treatment, supporting its broader migraine portfolio.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 59.8% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 14.3% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.9% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
Key Takeaways
AbbVie (ABBV - Free Report) announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin gene-related peptide receptor antagonist, for preventive treatment of menstrual migraine in adult women. Menstrual migraine is a recurrent and debilitating form of migraine associated with attacks occurring around or during menstruation.
Atogepant is already approved in the United States as Qulipta for the preventive treatment of migraine in adults, while the drug is marketed as Aquipta in the European Union for acutetreatment and migraine prophylaxis in adults.
Year to date, ABBV shares have risen 11.6% compared with the industry’s 10.4% growth.
Image Source: Zacks Investment Research
ABBV’s Atogepant Reports Positive Data Across LUNA Endpoints
The phase III LUNA study evaluated atogepant for the prevention of menstrual migraine in adult women with either pure menstrual migraine or menstrually related migraine. Participants were given atogepant for seven days around the start of their menstrual period for three consecutive cycles.
Atogepant met the study’s primary endpoint, reducing migraine days during the perimenstrual period by an average of 1.20 days compared with 0.40 days with placebo. This resulted in 0.80 fewer migraine days versus placebo.
The drug demonstrated statistically significant and clinically meaningful improvements across the study’s secondary endpoints, including reductions in headache days, moderate-to-severe headache and migraine severity, as well as decreased use of acute migraine medications. Improvements were also observed in functional disability, cognitive function and responder rates. The safety profile remained consistent with the established profile of atogepant, with no new safety signals reported.
AbbVie plans to submit the study data to regulatory authorities worldwide and present the detailed results at future medical meetings.
With no treatment specifically approved for menstrual migraine, the LUNA findings could help address an important unmet need while potentially expanding the commercial opportunity for AbbVie’s established migraine franchise.
LUNA Data Could Expand Atogepant’s Commercial Opportunity
The LUNA study data are particularly important from a commercial perspective because they could broaden the addressable market for Qulipta/Aquipta. Qulipta/Aquipta is already an important growth product within AbbVie’s neuroscience portfolio. It is approved across 60 countries.
In the second quarter of 2026, global Qulipta/Aquipta net revenues reached $350 million, up 30.9% year over yearon a reported basis, while first-half 2026 revenues reached $646 million, representing 40.5% reported growth year over year.
AbbVie markets Ubrelvy (ubrogepant) for acute migraine treatment, supporting its broader migraine portfolio.
ABBV’s Zacks Rank & Stocks to Consider
AbbVie currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 59.8% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 14.3% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.9% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.